Supplementary Table S3 from A Novel Combination Treatment Targeting BCL-X&lt;sub&gt;L&lt;/sub&gt; and MCL1 for &lt;i&gt;KRAS/BRAF&lt;/i&gt;-mutated and &lt;i&gt;BCL2L1&lt;/i&gt;-amplified Colorectal Cancers